A Call for Implementation Science: Achieving Equitable Access to SGLT2 Inhibitors

Sophie E Claudel; Insa M Schmidt; Ashish Verma

doi:10.34067/KID.0001512022

A Call for Implementation Science: Achieving Equitable Access to SGLT2 Inhibitors

Kidney360. 2022 Mar 2;3(5):942-944. doi: 10.34067/KID.0001512022. eCollection 2022 May 26.

Authors

Sophie E Claudel¹, Insa M Schmidt², Ashish Verma²

Affiliations

¹ Department of Internal Medicine, Boston Medical Center, Boston, Massachusetts.
² Section of Nephrology, Department of Internal Medicine, Boston Medical Center, Boston, Massachusetts.

No abstract available

Keywords: SGLT2i; chronic kidney disease; diabetes; diabetes and the kidney; disparity; equity; implementation science; sodium-glucose transporter 2 inhibitors.

MeSH terms

Canagliflozin / pharmacology
Implementation Science
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin

Grants and funding

R38 HL143584/HL/NHLBI NIH HHS/United States